We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
If countries with strict drug-pricing regulations were to encourage a competitive generic drug industry, they could realize savings that equal or exceed those gained through price controls, according to the Generic Pharmaceutical Association (GPhA).
Illinois lawmakers have passed legislation that removes the ability of a state pharmaceutical advisory panel to block FDA-approved generic drugs from being substituted for their brand counterparts.
Bayer Biological Products (Bayer BP) is employing innovative antitampering strategies as part of the company’s ongoing effort to combat product tampering and counterfeiting.
Injectable drugmaker Hospira, which was created last year from the hospital-products business of Abbott Laboratories, is the latest firm to join the Generic Pharmaceutical Association (GPhA), whose members increasingly make more than just generic products.
Intellectual property protections in the new U.S. free trade deal with Morocco will encourage brand firms to invest in the North African country and lead to a stronger generic drug industry there, according to U.S. trade officials.
Multiple generic firms are lining up to launch versions of Abbott Laboratories’ profitable antibiotic Biaxin once the basic patent expires next May, but expected legal moves by Abbott could delay generic entry, experts say.
Mylan Laboratories plans to acquire King Pharmaceuticals in a $4 billion stock swap that will give Mylan access to four of King’s brand drugs, which generate sales more than $100 million each.
If foreign governments were to implement aggressive generic substitution measures, they would likely realize savings that equal or exceed those gained through price controls, according to the Generic Pharmaceutical Association (GPhA).
The FDA has refused to prohibit the marketing and distribution of brand-authorized generic drugs during another generic firm’s 180-day exclusivity period for the same product — a move that will likely prompt a lawsuit against the agency.
Generic heavyweight Mylan Laboratories plans to acquire drugmaker King Pharmaceuticals in a $4 billion stock swap that will give Mylan access to four of King’s brand products, which generate annual sales of more than $100 million each.